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Abstract
Genotyping arrays are a cost effective approach when typing previously-identified genetic polymorphisms in large numbers
of samples. One limitation of genotyping arrays with rare variants (e.g., minor allele frequency [MAF] ,0.01) is the difficulty
that automated clustering algorithms have to accurately detect and assign genotype calls. Combining intensity data from
large numbers of samples may increase the ability to accurately call the genotypes of rare variants. Approximately 62,000
ethnically diverse samples from eleven Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)
Consortium cohorts were genotyped with the Illumina HumanExome BeadChip across seven genotyping centers. The raw
data files for the samples were assembled into a single project for joint calling. To assess the quality of the joint calling,
concordance of genotypes in a subset of individuals having both exome chip and exome sequence data was analyzed. After
exclusion of low performing SNPs on the exome chip and non-overlap of SNPs derived from sequence data, genotypes of
185,119 variants (11,356 were monomorphic) were compared in 530 individuals that had whole exome sequence data. A
total of 98,113,070 pairs of genotypes were tested and 99.77% were concordant, 0.14% had missing data, and 0.09% were
discordant. We report that joint calling allows the ability to accurately genotype rare variation using array technology when
large sample sizes are available and best practices are followed. The cluster file from this experiment is available at www.
chargeconsortium.com/main/exomechip.
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Introduction
Exome- and whole-genome sequencing is becoming increasing-
ly affordable and allows for detection and genotyping of rare
variants in the human genome. Yet, genotyping arrays remain a
cost-effective approach when investigating genetic polymorphisms
previously identified in large populations. A limitation of using
arrays to genotype rare variants is the difficulty that automated
clustering algorithms have to accurately detect and assign accurate
genotype calls [1,2]. Large sample sizes increase the number of
occurrences of rare variants and, therefore, should facilitate
automated clustering and genotyping.
An array focused on rare and low frequency coding variation,
hereafter referred to as the exome chip, has been developed by
querying the exomes sequenced in ,12,000 individuals and
aggregating the variation that is seen in more than two individuals
in more than two sequencing efforts (http://genome.sph.umich.
edu/wiki/Exome_Chip_Design). Participating studies in the
Cohorts for Heart and Aging Research in Genomic Epidemiology
(CHARGE) Consortium [3] consented to have their Illumina
Infinium HumanExome BeadChip intensity data analyzed
collectively (n=62,266) in order to increase the accuracy of rare
variant genotype calls. The resulting cluster file (.egt) is publically
available and we show that its use, along with best practices,
increase genotype accuracy compared to other methods alone.
Results
Genotypes were obtained for 238,876 successful variants in
accordance with our best practices (96.4% SNP pass rate) which
were converted to PLINK format [4] by cohort and combined into
a single aggregate file for further analyses. Of the 62,266 samples
genotyped, 1,380 (2.2%) had a GenCall quality score in the lower
10
th percentile of the distribution across all variants genotyped
(p10GC) ,0.38 or call rate ,0.97 and were excluded from allele
frequency calculations. Because founder effects and unique
population structure have been previously observed in Icelandic
samples [5,6], the Age, Gene/Environment, Susceptibility-Rey-
kjavik study was excluded from subsequent steps. Known
duplicated samples, individuals without self-reported race, and
the HapMap controls were also removed. After excluding
duplicate variants (n=811), the minor allele frequencies (MAF)
for 238,065 successful SNPs and 56,407 samples by self-reported
race are described in Table 1. There were 10,693 monomorphic
SNPs (4.5%), and 78.6% of the variants on the exome chip have a
MAF ,0.005. Allele frequencies for each variant by race group
are reported in the SNP information file (see Methods and Data
Access sections). Ethnicity specific HapMap allele frequencies for
the 96 controls (48 CEU and 48 YRI) and genotypes are also
available.
CHARGE Exome Chip Best Practices
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approach (see Methods), we compared exome chip genotypes
derived from three calling methods to available exome
sequencing data in 530 ARIC individuals. First, exome chip
genotypes were called with the Illumina issued cluster file
HumanExome-12v1.egt (see Data Access section for file
location) (Dataset I). Second, we used zCall (threshold set to
7) [7] to determine genotypes for the missing variant calls in
Dataset I to create Dataset Z. Third, we used the CHARGE
best practices (see Data Access) and joint calling approach
described to ascertain exome chip genotypes (Dataset C). A total
of 185,119 variants that were present in the exome sequence
dataset and passed our best practices were compared using
genotype concordance and uncertainty coefficient tests. Results
are presented in Table 2. The uncertainty coefficients indicate
that we can predict 86.4% of the information (entropy) in the
exome sequence data when using the Illumina cluster file,
91.2% when using the zCall algorithm, and 93.4% when the
CHARGE clustering method was utilized.
These data demonstrate the importance of implementing
stringent laboratory quality control measures in addition to the
clustering algorithms and rare variant calling approaches tested.
The complete list of 8,994 failing SNPs identified in the jointly
called exome chip project are available for download on the
CHARGE public website. Genotypes ascertained with the
CHARGE jointly called exome chip cluster file (Dataset C) were
99.77% concordant with sequence data, 0.14% were missing in
exome chip data, in the exome sequence data, or both, and 0.09%
were discordant (Figure 1). Heterozygotes in Dataset C were most
often misclassified when compared to the common allele
homozygote, and mismatches were attributed equally to both
sequencing and genotyping (Table 2).
We also tested the ability of the CHARGE exome chip cluster
file to accurately assign genotypes in the three rarest variant bins:
singletons (minor allele count=1), doubletons (minor allele
count=2), and tripletons (minor allele count=3). We observed
high concordance between exome chip singletons (99.99%),
doubletons (99.98%), and tripletons (99.97%) when compared to
their respective sequence genotypes in the same 530 ARIC
individuals previously described (data not shown). These results
are consistent with the global concordance tests which suggest we
are able to accurately call very rare variants.
Discussion
The results presented here demonstrate that rare variants on the
exome chip can be accurately called when using a large, combined
cluster file and best practices described when compared to existing
clustering algorithms and rare variant calling methods. The joint
calling protocol, accompanying cluster file, list of poor performing
variants on the chip, and annotation data are a valuable resource
for the scientific community and will be of great utility to those
having smaller sample sets where the calling of rare variants is
problematic. All new projects will require user decisions based on
their own cohort data and the metrics and best practices presented
here should be updated accordingly.
Materials and Methods
Subjects
Data from 62,266 participants from the following eleven studies
in the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium [3] were included in this
joint calling experiment and study descriptions were published
previously: Age, Gene/Environment, Susceptibility-Reykjavik
(AGES) Study [8], Atherosclerosis Risk in Communities (ARIC)
Study [9], Cardiac Arrest Blood Study (CABS) [10], Cardiovas-
cular Health Study (CHS) [11,12], Coronary Artery Risk
Development in Young Adults (CARDIA) [13,14], Multi-Ethnic
Study of Atherosclerosis (MESA) [15], Family Heart Study
(FamHS) [16], Framingham Heart Study (FHS) [17], Health,
Aging, and Body Composition (HABC) Study [18], Jackson Heart
Study (JHS) [19], and the Rotterdam Study (RS) [20–23]. In
addition, we genotyped 96 unrelated HapMap samples (48 CEU
and 48 YRI) with each cohort and the list of sample IDs are
available as a reference on the CHARGE exome chip public
website.
Ethics Statement
All subjects provided written and informed consent to partic-
ipate in genetic studies, and all study sites received approval to
conduct this research from their local respective Institutional
Review Boards (IRB) as follows: ’’The National Bioethics
Committee‘‘ and ’’The Data Protection Authority‘‘ (AGES);
University of Mississippi Medical Center IRB (ARIC – Jackson
Field Center), Wake Forest University Health Sciences IRB (ARIC
– Forsyth County Field Center), University of Minnesota IRB
Table 1. Exome chip minor allele frequency distribution by race.
MAF Interval African Americans Caucasians Hispanics Asians All
(n=13,375) (%) (n=40,102) (%) (n=2,128) (%) (n=776) (%) (n=56,407) (%)
0 23.6 16.5 43.6 77.5 4.5
(0, 0.001] 36.8 58.1 22.3 3.9 58.8
(0.001, 0.005] 14.6 8.6 13.9 3.9 15.3
(0.005, 0.01] 4.4 2.3 3.7 1.6 4.3
(0.01, 0.05] 7.9 3.8 5.1 3.0 5.7
(0.05, 0.1] 2.7 1.7 1.7 1.4 1.8
(0.1, 0.2] 3.0 2.4 2.4 2.1 2.4
(0.2, 0.5] 7.1 6.7 7.3 6.6 7.3
The following samples were excluded: all AGES individuals, race unknown or not reported, known replicates, HapMap controls, individuals with p10GC ,0.38, and
individuals with call rate ,0.97. Individuals with race designated as other were included in the overall MAF calculation, but data is not shown separately (n=26). A total
of 238,065 variants were used for calculating minor allele frequencies after excluding those that failed laboratory quality control (n=8,994) and duplicates (n=811).
doi:10.1371/journal.pone.0068095.t001
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(Bloomberg School of Public Health) IRB (ARIC – Washington
County Field Center); University of Washington IRB (CABS);
Wake Forest University Health Sciences IRB (CHS – Forsyth
County Field Center), University of California, Davis IRB (CHS –
Sacramento County Field Center), Johns Hopkins University
(Bloomberg School of Public Health) IRB (CHS – Washington
County Field Center), and University of Pittsburgh IRB (CHS –
Pittsburgh Field Center); University of Alabama at Birmingham
(CARDIA – Birmingham Field Center), Northwestern University
IRB (CARDIA – Chicago Field Center), University of Minnesota
IRB (CARDIA – Minneapolis Field Center), and Kaiser
Permanente IRB (CARDIA – Oakland Field Center); Washington
University IRB (FamHS); Boston University IRB (FHS); Wake
Forest University Health Sciences IRB (HABC); University of
Mississippi Medical Center IRB (JHS); Columbia University IRB
(MESA – New York Field Center), Johns Hopkins University IRB
(MESA – Baltimore Field Center), Northwestern University IRB
(MESA – Chicago Field Center), University of California IRB
(MESA – Los Angeles Field Center), University of Minnesota IRB
(MESA – Twin Cities Field Center), Wake Forest University
Health Sciences IRB (MESA – Winston-Salem Field Center) and
the National Heart, Lung, and Blood Institute; Medisch Ethische
Toetsings Commissie (METC) at the Erasmus Medical Center,
and the Netherlands Ministry of Health, Welfare and Sport (VWS)
(RS). Joint calling of the array data was approved by the
Committee for the Protection of Human Subjects (CPHS) which
serves as the IRB for the University of Texas Health Science
Center at Houston.
Genotyping
Study samples were processed on the HumanExome BeadChip
v1.0 (Illumina, Inc., San Diego, CA) querying 247,870 variable
sites described elsewhere (see Data Access) using standard
protocols suggested by the manufacturer at the following seven
genotyping centers: Broad Institute (JHS), Cedars-Sinai Medical
Center (CHS, FamHS and MESA), Erasmus Medical Center (RS),
Illumina Fast Track Services (FHS), University of Texas Health
Science Center at Houston (AGES, ARIC and CARDIA),
University of Washington (CABS), and Wake Forest University
(HABC). Each center genotyped a common set of 96 HapMap
samples to be utilized for quality control and determination of
batch effects. The two channel raw data files (.idat) for all samples
were transferred to a central location and assembled into a single
project for joint calling. A summary of the samples genotyped
within each cohort by race and gender is described in Table 3.
Table 2. Results of missing data, genotype discordance, uncertainty coefficients and frequencies of exome chip data ascertained
by three calling methods and compared to exome sequence genotypes.
Exome Sequence Exome Chip Missing Discordance Uncertainty
Genotypes Genotypes (%) (%) Coefficient
Dataset I AA AB BB XX Total
AA 94,878,501 33,679 4,467 183,952 95,100,599
AB 41,395 2,350,644 4,777 15,967 2,412,783
BB 3,658 4,642 495,626 1,809 505,735
XX 89,104 2,905 711 1,233 93,953
Total 95,012,658 2,391,870 505,581 202,961 98,113,070 0.30 0.09 0.864
Dataset Z AA AB BB XX Total
AA 94,964,611 115,849 4,394 15,745 95,100,599
AB 41,864 2,365,462 5,137 320 2,412,783
BB 3,557 5,635 496,351 192 505,735
XX 89,480 2,996 714 763 93,953
Total 95,099,512 2,489,942 506,596 17,020 98,113,070 0.11 0.18 0.912
Dataset C AA AB BB XX Total
AA 95,023,653 33,442 4,430 39,074 95,100,599
AB 41,850 2,363,664 3,969 3,300 2,412,783
BB 3,606 4,646 496,897 586 505,735
XX 89,391 2,930 706 926 93,953
Total 95,158,500 2,404,682 506,002 43,886 98,113,070 0.14 0.09 0.934
A total of 185,119 variants were used for these analyses, excluding duplicated variants, short insertion/deletions, XY chromosome SNPs, Y chromosome SNPs,
mitochondrial SNPs, sites not identified in the exome sequencing dataset, and failing SNPs as identified by the CHARGE best practices guidelines. Genotype classes are
represented as AA=common variant homozygote, AB=heterozygote, BB=rare variant homozygote, and XX=missing data. Dataset I: exome chip genotypes called
with Illumina cluster file. Dataset Z: zCall assigned genotypes to missing data in Dataset I. Dataset C: exome chip genotypes called with the CHARGE cluster file.
doi:10.1371/journal.pone.0068095.t002
Figure 1. Results of CHARGE exome chip genotype calls
compared to exome sequence data in 530 individuals.
doi:10.1371/journal.pone.0068095.g001
CHARGE Exome Chip Best Practices
PLOS ONE | www.plosone.org 4 July 2013 | Volume 8 | Issue 7 | e68095The following variables were provided for each sample included in
the project: study specific sample ID, cohort name, sample type
(DNA or WGA), race (self-reported), gender, sample plate, sample
well, chip barcode, chip position, replicate ID, father and mother
IDs (if applicable).
Clustering, Genotype Calling and Laboratory Quality
Control
The Illumina GenomeStudio v2011.1 software was utilized with
the GenTrain 2.0 clustering algorithm. Genomic DNA study
samples and HapMap controls with call rates .99% (n=55,142)
were used to define genotype clusters with races combined and
reruns excluded. The no-call threshold was set to 0.15 and we
excluded female Y SNPs when calculating SNP statistics. The
genotype quality score, representing the 10
th percentile of the
distribution of GenCall scores across all SNPs genotyped (p10GC),
was visually examined in a scatter plot across all samples (Index vs.
p10GC). Samples with an empirically determined p10GC ,0.38
were identified as outliers and flagged for exclusion. The SNP
parameters ‘‘Expected Number of Clusters of Y SNPs’’ and
‘‘Expected Number of Clusters of mtSNPs’’ were set to 2.
Following automated clustering, all variants meeting the criteria
provided in Table 4 (n=107,175) were visually inspected and
manually clustered, if possible, by two independent laboratory
technicians. AA and BB theta deviation cutoffs were determined
empirically. Variants removed from the HumanExome BeadChip
v1.1 (n=4,969) and cautious sites, as defined by the exome chip
design committee (n=333) (ftp://share.sph.umich.edu/
exomeChip/IlluminaDesigns/cautiousSites/cautiousSite.sorted.
sites), were also inspected. Samples with a call rate between 0.95
and 0.99 that had been previously excluded were brought back in
to the project and re-inspected based on the criteria listed in
Table 4. This additional review was necessary as the CHARGE
exome chip project contains samples from multiple DNA sources
and ethnicities that were genotyped at several centers. SNPs
exhibiting obvious batch effects were excluded. After joint calling,
reproducibility and heritability statistics, SNP statistics and sample
statistics were updated and the SNP-level quality control criteria
described in Table 5 were implemented. SNPs with reproducibility
(rep) errors .2, parent-parent-child (PPC) error .1, or parent-
child (PC) error .1 were not excluded, but were flagged and
reported back to the participating studies for further investigation.
A list of the 8,994 excluded variants is provided on the CHARGE
exome chip website as cluster positions for these sites are zeroed
out in the.egt file (note: all SNP statistics for these sites will be
converted to zero when the cluster file is imported into the
Genome Studio project). A portion of excluded SNPs may be
recoverable in projects with a homogenous population substruc-
ture, and we recommend clustering and reviewing the subset of
variants with the user’s high quality samples. Table 6 describes the
exome chip content and number of variants excluded by
functional category (see Annotation). Importantly, the v1.0 cluster
file should not be used for calling the Illumina v1.1 exome chip as
the two versions were manufactured with different bead pools.
Exome Chip Performance
Genotypes derived from available exome sequencing of 540
ARIC participants were used as the comparison dataset to test the
performance of the exome chip. We excluded 10 individuals from
the sequencing dataset due to a high missing data rate ,0.90, or
non-overlap of individuals with existing exome chip data. Exome
sequencing data is accessible via dbGaP as part of the National
Heart Lung and Blood Institute (NHLBI) GO-ESP: Heart Cohorts
Component of the Exome Sequencing Project (ARIC) (Study
Accession: phs000398.v1.p1).
The following variants were excluded from the exome chip
dataset as they were not available in the genotype data derived
from exome sequencing results: replicate sites that were deter-
mined as triallelic or duplicates on opposite strands, short
insertion/deletions, XY chromosome SNPs, Y chromosome SNPs,
mitochondrial SNPs, or sites not identified in the exome
sequencing dataset (n=56,042). Poor performing variants identi-
fied by our best practices criteria were removed if not previously
excluded (n=6,709), thus a total of 185,119 variants were
available for concordance analyses in 530 individuals.
Since concordance results are potentially high due to rare
variation on the exome chip, we also calculated uncertainty
coefficients [24] to determine the degree of association between
each of the exome chip calling methods and exome sequence data.
The uncertainty coefficient is a measure of association that is based
Table 3. Sample sizes of cohorts participating in joint calling effort by gender and self-reported race.
Cohort African Americans Caucasians Hispanics Asians Other HapMaps Replicates Total
M F M F MF MF M F M F MF U
1
AGES 0 0 1,305 1,767 0 0 0 0 0 0 24 24 6 9 0 3,135
ARIC 1,121 1,832 5,198 5,873 0 0 0 0 0 0 77 76 62 90 200 14,529
CABS 283 172 3,701 1,174 0 0 0 0 0 0 57 59 93 29 0 5,568
CHS 318 526 2,008 2,603 0 0 1 3 14 13 48 46 25 34 0 5,639
CARDIA 900 1,185 1,063 1,189 0 0 0 0 0 0 48 48 18 30 0 4,481
FamHS 213 409 933 1,191 0 0 0 0 0 0 14 23 1 0 0 2,784
FHS 0 0 3,702 4,475 0 0 0 0 0 0 75 69 47 76 0 8,444
HABC 515 680 930 839 0 0 0 0 0 0 48 47 7 5 0 3,071
JHS 1,063 1,795 0 0 0 0 0 0 0 0 64 64 0 0 0 2,986
MESA 1,129 1,464 1,282 1,397 978 1,151 387 386 0 0 44 44 51 39 0 8,352
RS 0 0 1,459 1,720 0 0 0 0 0 0 47 47 0 0 4 3,277
Total 5,542 8,063 21,581 22,288 978 1,151 388 389 14 13 546 547 310 312 204 62,266
1Gender is unavailable for blinded replicates in the ARIC study and four RS samples.
doi:10.1371/journal.pone.0068095.t003
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variable, that is, a variable subject to chance variations.
Uncertainty coefficients are useful when evaluating results
obtained from clustering algorithms since genotype classification
is usually random (all minor alleles are not classified as either AA
or BB), thus the algorithm is not susceptible to rare variation bias
in which the more common genotype could have been called by
chance alone. See Press et al. (1992), pp. 758–762, for further
clarification of the uncertainty coefficient metric [26].
Annotation
Annotation of the v1.0 exome chip variants was performed with
dbNSFP [27]. The dbNSFP v2.0 annotations are available on the
CHARGE exome chip public website in the SNP information file.
dbSNP rs information has been curated and a look up table with
the associated Illumina SNP name is also available. The reason for
inclusion of the variant on the exome chip by the design team is
also provided in the SNP info file (ftp://share.sph.umich.edu/
exomeChip/IlluminaDesigns/annotatedList.txt).
Data Access
The following CHARGE supporting documents are located at
chargeconsortium.com/main/exomechip: CHARGE_Exome-
Chip_Best_Practices.pdf, CHARGE_ExomeChip_v1.0_Cluster_-
File.egt (cluster file for v1.0 chip), CHARGE_ExomeChip_-
v1.0_Excluded_Variants.txt (list of 8,994 zeroed out variants in
Table 4. Best practices criteria used to identify SNPs for visual
inspection and manual reclustering.
Best Practices Criteria
All X, Y, XY and MT variants
Call frequency between 0.95 and 0.99
Cluster separation ,0.4
AB frequency .0.6
AB R mean ,0.2
Het excess .0.1
Het excess,20.9
AA theta mean between 0.2 and 0.3
BB theta mean between 0.7 and 0.8
AB theta mean between 0.2 and 0.3
AB theta mean between 0.7 and 0.8
AA theta deviation .0.025
AB theta deviation $0.07
BB theta deviation .0.025
AB frequency=0 and minor allele frequency .0
AA frequency=1 and call rate ,1
BB frequency=1 and call rate ,1
MAF ,0.0001 and call rate ? 1
Rep error .2
PPC error .1
PC error .1
Variants removed from v1.1 exome chip
Cautious sites
AA: allele A homozygote; AB: heterozygote; BB: allele B homozygote; Het:
heterozygote; MAF: minor allele frequency; MT: mitochondrial; PC: parent-child;
PPC: parent-parent-child; R: normalized intensity; Rep, reproducibility.
doi:10.1371/journal.pone.0068095.t004
Table 5. Exome chip SNP exclusion criteria.
Exclusion Criteria
Call frequency ,0.95 (except Y chr)
Cluster separation ,0.4
AB frequency .0.6
AB R mean ,0.2
Het excess .0.1
Het excess,20.9
AA theta mean .0.3
BB theta mean ,0.7
AB theta mean ,0.2 or .0.8
AA theta deviation .0.06
AB theta deviation $0.07
BB theta deviation .0.06
Obvious batch effects
AA: allele A homozygote; AB: heterozygote; BB: allele B homozygote; Het:
heterozygote; R: normalized intensity.
doi:10.1371/journal.pone.0068095.t005
Table 6. Exome chip content and CHARGE excluded variants
by functional category.
Category
1 Total Variants Variants Excluded
exonic;stopgain 5,193 145
exonic;splicing;stopgain 90 1
exonic;stoploss 239 2
exonic;splicing;stoploss 5 0
splicing 2,263 60
exonic;splicing;synonymous 3,363 74
exonic;splicing 70 1
exonic;splicing;nonsynonymous 5,237 105
exonic;nonsynonymous 208,779 7,369
exonic;synonymous 6,415 281
UTR3 518 46
UTR5 77 6
ncRNA_splicing 1 1
ncRNA_exonic 111 8
ncRNA_UTR3 8 0
ncRNA_UTR5 1 0
intronic 5,762 254
ncRNA_intronic 447 23
downstream 187 19
upstream 181 7
upstream;downstream 8 0
intergenic 8,549 528
indel 137 10
mitochrondrial 226 54
no annotation 3 0
Total 247,870 8,994
1dbNSFP was used for annotating variants [27] (see Methods).
doi:10.1371/journal.pone.0068095.t006
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Read Me file includes Illumina annotation, dbNSFP annotation,
dbSNP rs numbers, overlapping sites between the HumanExome
BeadChip v1.0 and v1.1, reason for inclusion, and race specific
allele frequencies for each variant, including HapMap controls.
Sample identifiers (CHARGE_ExomeChip_HapMap96_Con-
trol_List.csv) and genotypes for the 96 unrelated HapMap controls
(CHARGE_ExomeChip_HapMap96_Genotype_Data.csv) are al-
so available.
The Illumina genotyping protocol (Infinium_Best_Practices_
370-2009-010.pdf) and cluster file (HumanExome-12v1.egt) are
available with a MyIllumina login at https://icom.illumina.com/.
The exome chip content data sheet is publicly available at http://
www.illumina.com/documents/products/datasheets/datasheet_
humanexome_beadchips.pdf.
zCall is a rare variant caller for array-based genotyping
provided by Goldstein et al. and available for download at
github.com/jigold/zCall [7]. PLINK is a freely available analysis
toolset at http://pngu.mgh.harvard.edu/purcell/plink/ [4].
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